Greenwich LifeSciences announced two abstracts accepted for the SABCS 2026, showcasing its breast cancer immunotherapy trial findings.
Quiver AI Summary
Greenwich LifeSciences, Inc. has announced that two abstracts related to its Phase III clinical trial, FLAMINGO-01, evaluating the immunotherapy GLSI-100 for preventing breast cancer recurrences, have been accepted for publication at the San Antonio Breast Cancer Symposium (SABCS) 2026. The symposium will take place from December 8-11, 2026, where the posters will be presented on December 9 by the trial's Steering Committee. The company has also updated its website with various resources, including presentations and interviews related to the trial. SABCS is a significant conference expected to attract around 10,000 healthcare professionals from over 105 countries to discuss developments in breast cancer research.
Potential Positives
- Two abstracts accepted for publication at the San Antonio Breast Cancer Symposium (SABCS) 2026, enhancing the company's visibility in the oncology community.
- Poster presentations authored by the Steering Committee of the Phase III trial FLAMINGO-01, indicating strong support from key stakeholders within the clinical research field.
- Opportunity for increased engagement with approximately 10,000 healthcare professionals expected to attend the conference, potentially expanding networking and partnership opportunities.
- Updates to the company’s website with corporate slides and presentations, providing stakeholders with comprehensive insights into the trial's progress and corporate strategy.
Potential Negatives
- The announcement heavily relies on forward-looking statements, indicating potential uncertainties and risks regarding the success of their clinical trials and business projections.
- No detailed data or results from the Phase III trial were provided, which could leave investors and stakeholders without critical information to assess the company's progress and prospects.
FAQ
What is the purpose of the FLAMINGO-01 trial?
The FLAMINGO-01 trial is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences.
When will the SABCS 2026 take place?
The San Antonio Breast Cancer Symposium (SABCS) 2026 will be held from December 8-11, 2026.
What will be presented at SABCS 2026?
Two abstracts and corresponding poster presentations related to the FLAMINGO-01 trial will be presented.
Where can I find more information about Greenwich LifeSciences?
More information is available on Greenwich LifeSciences' website at www.greenwichlifesciences.com.
How can I follow Greenwich LifeSciences on social media?
You can follow Greenwich LifeSciences on Twitter at https://twitter.com/GreenwichLS.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GLSI Insider Trading Activity
$GLSI insiders have traded $GLSI stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GLSI stock by insiders over the last 6 months:
- SNEHAL PATEL (CEO and CFO) has made 5 purchases buying 7,300 shares for an estimated $97,003 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$GLSI Hedge Fund Activity
We have seen 32 institutional investors add shares of $GLSI stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUSSELL INVESTMENTS GROUP, LTD. removed 32,572 shares (-94.8%) from their portfolio in Q3 2026, for an estimated $587,924
- MAN GROUP PLC removed 28,068 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $658,475
- JANE STREET GROUP, LLC removed 27,694 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $499,876
- BLACKROCK, INC. added 26,137 shares (+5.4%) to their portfolio in Q3 2026, for an estimated $471,772
- SEI INVESTMENTS CO removed 26,088 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $612,024
- MARSHALL WACE, LLP removed 25,658 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $601,936
- MORGAN STANLEY removed 24,596 shares (-56.6%) from their portfolio in Q3 2026, for an estimated $443,957
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$GLSI Analyst Ratings
Wall Street analysts have issued reports on $GLSI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/21/2026
To track analyst ratings and price targets for $GLSI, check out Quiver Quantitative's $GLSI forecast page.
Full Release
STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for publication at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2026 along with two corresponding poster presentations.
The SABCS 2026 will be held from December 8-11, 2026. The posters will be presented on December 9, 2026 during the poster sessions for ongoing clinical trials and late breaking abstracts, with both posters being authored by the Steering Committee of FLAMINGO-01.
The posters will be provided on the Company's website during the conference when permitted to do so by SABCS. In addition, the following has been updated on the Company's website: Corporate slides, FLAMINGO-01 Phase III trial design, corporate presentation from investor conference, fireside chat, analyst commentary, interview which aired on Bloomberg/CNBC TV, and a patient and doctor interview at a clinical site participating in FLAMINGO-01.
About SABCS
The 49th annual SABCS has grown to be the industry's premier breast cancer conference for basic, translational, and clinical cancer research professionals. It is well-known for presenting the latest breast cancer data from all over the world. Approximately 10,000 health care professionals from more than 105 countries are expected to attend in 2026. For more information, please visit the conference website at: https://www.sabcs.org/
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email:
[email protected]
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email:
[email protected]